Surya Corp

8/12/2019 Surya Corp

1/13

11


2/13

The Company isone of the largest exporters

of Mint/Menthol derivativesRevenue of over USD 250 mm

SPL ranks398 in the prestigious

FORTUNE India 500 list &

Ranked no: 20 in

Indian Pharmaceutical Sector

Strong Internal Competencies

World class Manufacturing & R&D

Strong Supply Chain & fastest growing

company

Trusted IndianBrand

SPLAn Introduction

ProfessionallyManageSPLhas been awarded EXCELLENTSUPPLIER (Best Competitiveness)

AWARD OFTHE one of the biggest

Pharmaceutical manufacturers

in Hong KongYEAR by Bright Future

Pharmaceutical laboratories Ltd,!!


3/13

Surya Corp

Established in the year 1992, Surya Pharmaceutical Ltd today is one of the leading integrated and multi-

dimensional pharmaceutical group of India which is growing and expanding very fast

A stronghold in API- especially B-LACTUMS and CEPHALOSPORINES with 8 state of the art manufacturing

units

Largest producer & exporter of Menthol & menthol based products to more than 90 countries

Branded formulations with 6 SBUS Covering various Therapeutic segments including nutritional products

is operational at PAN India level.

Surya Corp. is having its own chain of retail pharmacy stores with the Brand name of VIVA spreaded over

North India.

At present We have 100 Pharmacy Stores which are likely to increase upto 250 by the end of 2011.

OTC / FMCG business venture is also launched.

A Group worth INR 1200 crores ( USD 250 millions)

3


4/13

SPL ranks 398 in the prestigious FORTUNE India 500 list

& Ranked no: 20 in Indian Pharmaceutical Sector


5/13

SPL has ranked 398 in the prestigious FORTUNE India 500 list! The

Fortune India 500 list features India`s LARGEST CORPORATIONS!

Not only that, it outranked Pharmaceutical giants like Aventis Pharma, Alembic, Arch Pharmalabs and AnkurDrugs to climb to number 20 in the top Drugs & Pharmaceuticals companies of India!

Companies in the Fortune 500 list are ranked on the parameters of both Revenue & Income, they are

ranked by their latest annual audited total income for the financial year ending on or before June 30,

2010. The Total Income includes Core Operating Income ( Net sales) plus other ExtraordinaryIncome. Audited results declared before October 31st, 2010 have been used for the calculations. The

numbers have been sourced from two corporate databases- the Centre for Monitoring of Indian

Economies Prowess and Capitaline Plus by Capital Market Publishers India.


6/13

Surya Group


7/13

Diabetic

Footwear

Personal

care

Diagnostic

and Medical

Devices

Foot Care

Medical

shoes for

diabetic

patients

Classical

Diabetic

Neuropat

hy

Skin

Care

Baby

Care

Lip Care

OTC

Health

Care

BP

Monitors

Glucose

Monitor

Brand The Power Brand Strategy

Skin

Care

Feeding

Bottles

Baby care

Sports

Nutrition

Supplement

Bodybuildin

g Nutrition

Weight

Managemen

t Nutrition


8/13

EXP ND

INNOV TECQUIRE

A Three Pronged Strategy for Sustaining

Growth

Strategic Intent To double revenues and profits in the next coming years.


9/13

SPLOn The Growth Path

Sales in crores 2004 to 2010

0

200

400

600

800

1000

1200

1400

Sales Growth

2004

20052006

2007

2008

2009

2010


10/13

Surya Pharmaceutical LtdGrowth Trends


11/13

Net Profit 2004 to 2010


12/13

Surya Pharmaceutical Ltd Annual Report

2009-2010 Cash & Net Profit


13/13

Documents

Surya Corp